homemarket Newsstocks NewsGland Pharma riding the wave of momentum with positive USFDA certification
Gland Pharma riding the wave of momentum with positive USFDA certification
Gland Pharma's recent achievements and positive developments have firmly positioned the company as a stock to watch. Its strategic advancements, as exemplified by the USFDA's positive observations and certification, have instilled a sense of optimism and confidence in the market.
One stock that has recently captured the attention of traders is Gland Pharma. With a market capitalisation of approximately Rs 28,000 crore and its inclusion in the S&P BSE 200 index, Gland Pharma seems to be on a path of upward momentum.
The stock's impressive performance was underscored by a 9 percent surge just on August 31, a remarkable feat considering it has rallied by an impressive 102 percent from its 52-week low of Rs 861.
The United States Food and Drug Administration (USFDA) issued two observations in favour of the company's Hyderabad plant. These observations were related to a product intended to be manufactured in a pen device form. The most recent news surrounding Gland Pharma has sent ripples of optimism throughout the market.
The excitement surrounding Gland Pharma reached new heights on August 24, 2023, after the company revealed that it had received an Establishment Inspection Report (EIR) from the USFDA, particularly for its Dundigal facility located near Hyderabad in Telangana. This report marks a crucial milestone, as it signifies the closure of an inspection conducted by the US health regulator between July 3 and July 14, 2023.
The significance of this achievement was highlighted by Gland Pharma's disclosure that the USFDA had awarded the company a Good Manufacturing Practice (GMP) certification in connection with the inspection conducted at the Dundigal facility.
Also Read | Gland Pharma Share Price: Stock up 20%, back above IPO price after June quarter earnings
The brokerage firm Bernstein has firmly placed their bet on the company's prospects, giving it an "outperform" rating. In their assessment, Bernstein pointed to the first-quarter margins, which exhibited a noteworthy improvement from 21 percent to 24 percent.
As traders assess the potential of Gland Pharma, it's essential to consider its position in relation to its 52-week high. The stock currently stands 33 percent away from its peak of around Rs 2,606.
In terms of valuations, Gland Pharma is trading at approximately 29 times the forward one-year estimate, a significant difference from its peak valuation of 44 times. These numbers paint a picture of the remarkable upside potential that Gland Pharma might be poised to unlock.
For more details, watch the accompanying video
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Prajwal Revanna's father in custody for alleged kidnapping and sexual abuse
May 4, 2024 7:53 PM
Delhi, Indore, Surat and Banswara — why these are the most challenging domains for Congress internally
May 4, 2024 1:53 PM
Congress nominee from Puri Lok Sabha seat withdraws, citing no funds from party
May 4, 2024 12:00 PM
Lok Sabha Polls '24 | Rahul Gandhi in Rae Bareli, why not Amethi
May 4, 2024 9:43 AM